JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
The content, articles and product information provided on this website are strictly educational and informational. They are intended to be used for in vitro research only. “In vitro” is a Latin phrase, “in glass,” that refers to research that is conducted outside of a living organism. Note, these products are not pharmaceuticals or medicines and have not been approved by the FDA for the diagnosis, treatment or prevention of any illnesses or disorders. These products are legally prohibited from human or animal consumption.
Tadalafil is a research compound studied in cell-based assay formats for its selective PDE5 enzyme inhibition, cGMP pathway disinhibition, and PKG activation. Published in vitro research characterizes its molecular interactions, binding affinity profiles, and downstream pathway engagement in defined cell model systems under controlled laboratory conditions.
Tadalafil acts via selective phosphodiesterase type 5 (PDE5) enzyme inhibition, resulting in cGMP pathway disinhibition and protein kinase G (PKG) activation. Competitive radioligand binding assays demonstrate high-affinity interactions with the PDE5 catalytic domain, with documented Ki values ranging from 1-5 nM in purified enzyme preparations. The compound exhibits selectivity profiles favoring PDE5 over related phosphodiesterase isoforms, with selectivity ratios exceeding 100-fold versus PDE6 and 1000-fold versus PDE11A in enzymatic activity assays.
In vitro binding kinetics studies reveal tadalafil's association and dissociation rates with PDE5 enzyme complexes. Radioligand displacement experiments utilizing [³H]tadalafil demonstrate slow dissociation kinetics, with dissociation half-lives extending beyond 2 hours in cell-free enzyme preparations at physiological temperature conditions. This extended residence time on the enzyme target correlates with prolonged inhibitory effects observed in cellular cGMP accumulation assays.
Surface plasmon resonance analyses confirm the compound's binding stoichiometry and thermodynamic parameters. Tadalafil exhibits single-site binding behavior with PDE5 homodimers, demonstrating apparent KD values consistent with functional IC50 determinations in phosphodiesterase activity assays.
Cell-based assays examining tadalafil's duration of action utilize various model systems including human umbilical vein endothelial cells (HUVECs), human corpus cavernosum smooth muscle cells, and engineered cell lines overexpressing PDE5. These studies employ washout protocols to assess compound residence time and reversibility of enzyme inhibition.
In HUVEC monolayers, tadalafil demonstrates sustained PDE5 inhibition following compound removal from culture medium. Intracellular cGMP accumulation remains elevated for 12-24 hours post-washout when cells are subsequently challenged with nitric oxide donors or natriuretic peptides. This prolonged response profile distinguishes tadalafil from shorter-acting PDE5 inhibitors in comparative studies.
Fluorescent analogs of tadalafil enable real-time monitoring of intracellular compound distribution and retention. Live-cell imaging studies reveal sustained cytoplasmic accumulation with gradual clearance kinetics extending over 18-36 hours in cultured smooth muscle cell preparations. The compound's lipophilic properties facilitate membrane permeation and intracellular retention, contributing to prolonged target engagement.
Downstream signaling analysis demonstrates tadalafil's effects on cGMP-dependent protein kinase activation and substrate phosphorylation. Western blot analysis of PKG substrate phosphorylation reveals sustained activation patterns correlating with PDE5 occupancy kinetics. Phosphorylation of vasodilator-stimulated phosphoprotein (VASP) at serine 239 serves as a biomarker for PKG pathway activation in cell-based studies.
Time-course experiments utilizing cyclic nucleotide immunoassays demonstrate biphasic cGMP elevation profiles following tadalafil treatment. Initial rapid accumulation occurs within 15-30 minutes, followed by sustained elevation persisting 18-24 hours in the presence of ongoing nitric oxide synthase activity.
Patch-clamp electrophysiology studies examine tadalafil's effects on calcium-activated potassium channel activity in vascular smooth muscle cell preparations. The compound's modulation of cGMP-PKG signaling influences calcium homeostasis through indirect mechanisms involving calcium-sensitive ion channel regulation. These effects demonstrate temporal persistence consistent with prolonged PDE5 inhibition kinetics.
Cross-comparison studies with structurally related PDE5 inhibitors highlight tadalafil's unique pharmacological profile. While sildenafil and vardenafil demonstrate 4-6 hour duration in cell washout experiments, tadalafil maintains significant enzyme inhibition for 24-36 hours under identical experimental conditions. This extended duration reflects distinct molecular interactions within the PDE5 binding pocket, as confirmed through crystallographic and molecular modeling studies.
In vitro research demonstrates tadalafil's prolonged duration of PDE5 enzyme inhibition through slow dissociation kinetics and extended intracellular retention. Cell-based assays consistently show 24-36 hour persistence of cGMP pathway modulation following compound washout, distinguishing it from shorter-acting phosphodiesterase inhibitors. These temporal pharmacology characteristics make tadalafil a valuable research tool for studying sustained cGMP signaling in various cell model systems and understanding the relationship between enzyme residence time and functional duration in phosphodiesterase research applications.
All content is intended for in vitro laboratory research purposes only. Not for human or animal consumption. Not intended to diagnose, treat, cure, or prevent any condition.
Forgot password?
Country: United States (US-only registration)
All products on this site are for Research, Development use only. Products are Not for Human consumption of any kind. The statements made within this website have not been evaluated by the US Food and Drug Administration. The statements and the products of this company are not intended to diagnose, treat, cure or prevent any disease.
ElementSarms is a chemical supplier. ElementSarms is not a compounding pharmacy or chemical compounding facility as defined under 503A of the Federal Food, Drug, and Cosmetic act. ElementSarms is not an outsourcing facility as defined under 503B of the Federal Food, Drug, and Cosmetic act.